SEphB4-HSA

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
SEphB4-HSA
Accession Number
DB14797
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins
Description

SEphB4-HSA is under investigation in clinical trial NCT02495896 (Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors).

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • RECOMBINANT EPHB4-HSA FUSION PROTEIN
Categories
Not Available
UNII
SO0RV2V6EJ
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Head and Neck Squamous Cell Carcinoma (HNSCC) / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Recurrent Gallbladder Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Gallbladder Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Gallbladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Unresectable Gallbladder Carcinoma / Unresectable Pancreatic Cancer1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentBladder Cancer Stage 0 / Bladder Cancer Stage I / Recurrent Bladder Carcinoma / Stage 0a Bladder Cancer AJCC v8 / Stage 0is Bladder Cancer AJCC v8 / Stage I Bladder Cancer AJCC v81
1RecruitingTreatmentAcute Lymphoblastic Leukaemia Recurrent / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Blasts 5 Percent or More of Bone Marrow Nucleated Cells / Myelodysplastic/Myeloproliferative Neoplasms / Philadelphia Chromosome Positive / Recurrent Adult Acute Myeloid Leukemia / Refractory Acute Lymphoblastic Leukemia / Refractory Acute Myeloid Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / T Acute Lymphoblastic Leukemia1
1RecruitingTreatmentHigh Risk, Locally-advanced Squamous Cell Carcinoma of Head and Neck1
1RecruitingTreatmentInfiltrating Bladder Urothelial Carcinoma / Recurrent Bladder Carcinoma / Stage I Prostate Cancer / Stage I Renal Cell Cancer / Stage II Bladder Urothelial Carcinoma / Stage II Renal Cell Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage III Renal Cell Cancer1
2Not Yet RecruitingTreatmentKaposi s Sarcoma (KS)1
2RecruitingTreatmentALK Gene Mutation / BRAF Gene Mutation / EGFR Gene Mutations / Head and Neck Squamous Cell Carcinoma (HNSCC) / Metastatic Head and Neck Carcinoma / Recurrent Head and Neck Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / ROS1 Gene Mutation / Stage III Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents / Metastatic Prostate Adenocarcinoma / Progressive Disease / Prostate Carcinoma Metastatic in the Bone / Prostate Carcinoma Metastatic in the Soft Tissue / PSA Progression / Stage IVB Prostate Cancer AJCC v8 / Testosterone Less Than 50 ng/dL1
2RecruitingTreatmentSkin Kaposi Sarcoma1
2RecruitingTreatmentStage IV Bladder Urothelial Carcinoma1
2TerminatedTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Recurrent Adult Acute Myeloid Leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on May 20, 2019 08:27 / Updated on November 02, 2019 03:26